A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure

Metabolic associated fatty liver disease (MAFLD) is the most common chronic liver disease, with an estimated prevalence of between 20 and 30% worldwide. Observational data supported by in vitro and pre-clinical animal models of MAFLD suggest meaningful differences in drug disposition in MAFLD patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Newman, Elise M., Rowland, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570165/
https://www.ncbi.nlm.nih.gov/pubmed/36233052
http://dx.doi.org/10.3390/ijms231911751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570165/
https://www.ncbi.nlm.nih.gov/pubmed/36233052
http://dx.doi.org/10.3390/ijms231911751

Ejemplares similares